Compare PLUS & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLUS | AMLX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 1996 | 2021 |
| Metric | PLUS | AMLX |
|---|---|---|
| Price | $85.95 | $17.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $20.11 |
| AVG Volume (30 Days) | 145.8K | ★ 1.2M |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 4.08 | N/A |
| Revenue | ★ $2,068,789,000.00 | $380,786,000.00 |
| Revenue This Year | $19.83 | N/A |
| Revenue Next Year | $4.36 | N/A |
| P/E Ratio | $20.88 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $58.39 | $4.41 |
| 52 Week High | $93.98 | $18.61 |
| Indicator | PLUS | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 66.24 | 64.35 |
| Support Level | $85.63 | $13.19 |
| Resistance Level | $91.86 | N/A |
| Average True Range (ATR) | 2.61 | 0.91 |
| MACD | 0.90 | 0.26 |
| Stochastic Oscillator | 97.75 | 83.26 |
ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.